Real-World Safety and Efficacy of 156 U – 195 U OnabotulinumtoxinA in Adults With Chronic Migraine: Results From the REPOSE Study
Abstract Background The phase 3 PREEMPT clinical trials confirmed the efficacy and safety of 155 U – 195 U onabotulinumtoxinA for individuals with chronic migraine (CM) and is the licensed dose in Canada and Europe. This analysis aimed to analyze the efficacy and safety parameters of 155 U – 195 U o...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BMC
2025-05-01
|
| Serija: | BMC Neurology |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12883-025-04087-7 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|